MedTrace Logo

Innate Immune Response During Community Acquired Pneumonia

NCT03379207 · Status: TERMINATED · Type: OBSERVATIONAL · Enrollment: 258

Last updated 2025-11-24

No results posted yet for this study

Summary

Community acquired pneumonia (CAP) is a major cause of morbidity and mortality worldwide. Despite recent improvement in acute management (specifically for administration of antibiotics) many severe presentations of pneumonia worsen, progressing to Acute Respiratory Distress Syndrome (ARDS), a clinical entity with 40% hospital mortality.

Dysregulation of immune response is thought to be largely implicated in severe pneumonia progressing to ARDS. Notably, experimental studies have recently suggested the implication of non-conventional T lymphocytes and innate cells in this immunopathology. However, no data are available in Humans in clinical settings.

This study aims to explore the role of non-conventional T cells in pneumonia and ARDS, in participants. For this purpose, 100 participants admitted to Intensive Care Unit (ICU) with a diagnosis of CAP will be included, and 50 "control" participants with no pneumonia nor shock. Presence and functionality of non-conventional T cells and innate cells will be explored using flow-cytometry and ex-vivo stimulation, alongside with cytokines productions. These analyses are conducted in the blood, and, for invasively ventilated participants, in tracheal aspirates or broncho-alveolar fluids if available. For each participants included, the analyses are conducted at different time-points during ICU stay: inclusion, day 3, day 8 and day 15. Moreover, participants with ARDS, for whom a post-ICU follow-up program is normally established after discharge, will have blood analysis from blood samples taken during the follow-up visit up to 8 months after inclusion.

Immunophenotypage and functionality of non-conventional T cells and innate cells will be compared to clinical parameters and their evolution, between "CAP" participants and "Control" participants", and for each participants, according to the different time-point of analysis, in order to better understand dynamic of innate immunity during pneumonia and ARDS.

Conditions

  • Community-acquired Pneumonia
  • Acute Respiratory Distress Syndrome
  • Innate Immunity

Interventions

OTHER

Blood samples

Blood samples for research purpose, taken whenever possible during blood sampling for routine purpose

OTHER

Tracheal Aspirates

Only for mechanically ventilated participants.

OTHER

Surplus of Broncho-alveolar lavage fluid

Only if performed for diagnosis purpose by the treating investigator : indication left at his discretion

Sponsors & Collaborators

  • University Hospital, Tours

    lead OTHER

Principal Investigators

  • Youenn JOUAN, MD-PHD · University of TOURS-INSERM U1100

Eligibility

Min Age
18 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2018-01-10
Primary Completion
2025-06-04
Completion
2025-06-04

Countries

  • France

Study Locations

More Related Trials

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT03379207 on ClinicalTrials.gov